Generate a tailored SOP for Dr. David Scheinberg. Improve your application with a focused, well-structured draft.
David Scheinberg, MD, PhD, serves as Chair of the Center for Experimental Therapeutics and Deputy Director of the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. He is known for his innovative work in developing novel targeted immunotherapies that leverage the immune system to combat cancer. His laboratory aims to advance these discoveries to human clinical trials, demonstrating a commitment to translating research into effective patient therapies. Scheinberg's research efforts have led to the development of alpha particle therapies, targeted beta emitters, and engineered vaccines, with several projects reaching various phases of clinical trials. Notable examples include the molecular nanogenerator designed to release alpha particles at cancer cells, which has shown promising results in clinical studies. In addition, he has contributed to the field by discovering TCR mimic antibodies for targeting intracellular proteins and developing prototype targeted nanosystems for drug delivery. Scheinberg is heavily engaged in collaborative efforts to speed up the discovery and development of new therapeutic agents for cancer treatment. His work continues to push the boundaries of cancer immunotherapy.
Center for Experimental Therapeutics, MSK • New York, NY
Leads the center's research in developing novel immunotherapies.
Administered through the Gerstner Sloan Kettering (GSK) Graduate School. The program focus is Cancer Biology and includes faculty from the Department of Molecular Pharmacology.